Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.39
MDT's Cash-to-Debt is ranked lower than
79% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. MDT: 0.39 )
Ranked among companies with meaningful Cash-to-Debt only.
MDT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.89 Max: No Debt
Current: 0.39
Equity-to-Asset 0.51
MDT's Equity-to-Asset is ranked lower than
69% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MDT: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
MDT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.63 Max: 0.82
Current: 0.51
0.37
0.82
Debt-to-Equity 0.67
MDT's Debt-to-Equity is ranked lower than
77% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 0.29 vs. MDT: 0.67 )
Ranked among companies with meaningful Debt-to-Equity only.
MDT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.32 Max: 1.43
Current: 0.67
0.02
1.43
Interest Coverage 5.01
MDT's Interest Coverage is ranked lower than
84% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. MDT: 5.01 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s Interest Coverage Range Over the Past 10 Years
Min: 3.82  Med: 9.97 Max: 13.18
Current: 5.01
3.82
13.18
Piotroski F-Score: 7
Altman Z-Score: 2.28
Beneish M-Score: -2.53
WACC vs ROIC
5.04%
6.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 18.55
MDT's Operating Margin % is ranked higher than
86% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. MDT: 18.55 )
Ranked among companies with meaningful Operating Margin % only.
MDT' s Operating Margin % Range Over the Past 10 Years
Min: 16.71  Med: 21.89 Max: 26.53
Current: 18.55
16.71
26.53
Net Margin % 13.75
MDT's Net Margin % is ranked higher than
81% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. MDT: 13.75 )
Ranked among companies with meaningful Net Margin % only.
MDT' s Net Margin % Range Over the Past 10 Years
Min: 12.27  Med: 17.27 Max: 22.35
Current: 13.75
12.27
22.35
ROE % 8.19
MDT's ROE % is ranked higher than
64% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. MDT: 8.19 )
Ranked among companies with meaningful ROE % only.
MDT' s ROE % Range Over the Past 10 Years
Min: 6.72  Med: 18.07 Max: 22.29
Current: 8.19
6.72
22.29
ROA % 4.16
MDT's ROA % is ranked higher than
65% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. MDT: 4.16 )
Ranked among companies with meaningful ROA % only.
MDT' s ROA % Range Over the Past 10 Years
Min: 3.43  Med: 9.65 Max: 11.99
Current: 4.16
3.43
11.99
ROC (Joel Greenblatt) % 63.27
MDT's ROC (Joel Greenblatt) % is ranked higher than
89% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. MDT: 63.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.21  Med: 63.31 Max: 76.89
Current: 63.27
51.21
76.89
3-Year Revenue Growth Rate 8.40
MDT's 3-Year Revenue Growth Rate is ranked higher than
62% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. MDT: 8.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.2  Med: 13.9 Max: 18.6
Current: 8.4
4.2
18.6
3-Year EBITDA Growth Rate 8.30
MDT's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. MDT: 8.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MDT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -15.5  Med: 13.2 Max: 45.5
Current: 8.3
-15.5
45.5
3-Year EPS without NRI Growth Rate -1.50
MDT's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. MDT: -1.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MDT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 15.6 Max: 27.1
Current: -1.5
-9.7
27.1
GuruFocus has detected 5 Warning Signs with Medtronic PLC $MDT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MDT's 30-Y Financials

Financials (Next Earnings Date: 2017-11-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MDT Guru Trades in Q3 2016

Ray Dalio 31,000 sh (New)
Eaton Vance Worldwide Health Sciences Fund 665,629 sh (New)
Ken Fisher 4,949 sh (+4.94%)
Jeremy Grantham 4,593,000 sh (+3.33%)
Paul Tudor Jones 4,100 sh (+2.50%)
Keeley Asset Management Corp 11,133 sh (unchged)
T Rowe Price Equity Income Fund 750,000 sh (unchged)
John Hussman 125,000 sh (unchged)
David Carlson 930,000 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Jeff Auxier 139,123 sh (-0.04%)
Mairs and Power 2,960,586 sh (-1.14%)
Vanguard Health Care Fund 18,747,933 sh (-2.15%)
PRIMECAP Management 14,482,669 sh (-3.33%)
Diamond Hill Capital 2,385,913 sh (-3.42%)
Pioneer Investments 4,769,969 sh (-4.13%)
Manning & Napier Advisors, Inc 6,658,775 sh (-5.72%)
Barrow, Hanley, Mewhinney & Strauss 19,033,448 sh (-9.75%)
Ruane Cunniff 3,000 sh (-11.63%)
Dodge & Cox 5,584,858 sh (-13.44%)
Mario Gabelli 26,273 sh (-23.37%)
Robert Olstein 48,432 sh (-26.62%)
John Buckingham 16,032 sh (-26.69%)
Signature Select Canadian Fund 78,800 sh (-37.90%)
HOTCHKIS & WILEY 1,012,932 sh (-38.75%)
Bill Nygren 1,140,000 sh (-54.22%)
First Eagle Investment 397,038 sh (-64.10%)
Jim Simons 191,241 sh (-66.63%)
» More
Q4 2016

MDT Guru Trades in Q4 2016

Richard Pzena 4,287 sh (New)
Paul Tudor Jones 42,798 sh (+943.85%)
Jim Simons 878,141 sh (+359.18%)
T Rowe Price Equity Income Fund 1,810,000 sh (+141.33%)
Robert Olstein 110,000 sh (+127.12%)
Ray Dalio 62,300 sh (+100.97%)
Dodge & Cox 10,688,625 sh (+91.39%)
Bill Nygren 1,640,000 sh (+43.86%)
HOTCHKIS & WILEY 1,251,351 sh (+23.54%)
Ken Fisher 6,096 sh (+23.18%)
John Buckingham 18,321 sh (+14.28%)
Pioneer Investments 5,253,307 sh (+10.13%)
Diamond Hill Capital 2,615,402 sh (+9.62%)
Barrow, Hanley, Mewhinney & Strauss 20,528,595 sh (+7.86%)
Mairs and Power 3,142,079 sh (+6.13%)
Jeff Auxier 146,923 sh (+5.61%)
David Carlson 970,000 sh (+4.30%)
Vanguard Health Care Fund 19,256,523 sh (+2.71%)
Mario Gabelli 26,774 sh (+1.91%)
Manning & Napier Advisors, Inc 6,772,888 sh (+1.71%)
Ruane Cunniff 3,000 sh (unchged)
John Hussman 125,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 665,629 sh (unchged)
Keeley Asset Management Corp Sold Out
Jeremy Grantham 4,309,570 sh (-6.17%)
PRIMECAP Management 12,767,922 sh (-11.84%)
First Eagle Investment 1,434 sh (-99.64%)
» More
Q1 2017

MDT Guru Trades in Q1 2017

Joel Greenblatt 224,898 sh (New)
NWQ Managers 3,432 sh (New)
Steven Cohen 186,100 sh (New)
Caxton Associates 6,900 sh (New)
Louis Moore Bacon 25,000 sh (New)
T Rowe Price Equity Income Fund 2,750,000 sh (+51.93%)
Bill Nygren 2,440,000 sh (+48.78%)
Ken Fisher 7,109 sh (+16.62%)
Dodge & Cox 12,212,276 sh (+14.25%)
Mairs and Power 3,473,906 sh (+10.56%)
Robert Olstein 121,000 sh (+10.00%)
Richard Pzena 4,560 sh (+6.37%)
Jeff Auxier 147,023 sh (+0.07%)
Ruane Cunniff 3,000 sh (unchged)
First Eagle Investment 1,434 sh (unchged)
David Carlson 970,000 sh (unchged)
John Hussman Sold Out
Jim Simons Sold Out
Ray Dalio Sold Out
Diamond Hill Capital 2,597,862 sh (-0.67%)
John Buckingham 18,175 sh (-0.80%)
HOTCHKIS & WILEY 1,235,797 sh (-1.24%)
Barrow, Hanley, Mewhinney & Strauss 20,205,859 sh (-1.57%)
Pioneer Investments 5,132,545 sh (-2.30%)
Jeremy Grantham 4,205,711 sh (-2.41%)
Vanguard Health Care Fund 18,760,219 sh (-2.58%)
Mario Gabelli 25,861 sh (-3.41%)
PRIMECAP Management 11,093,565 sh (-13.11%)
Manning & Napier Advisors, Inc 5,665,135 sh (-16.36%)
Signature Select Canadian Fund 63,600 sh (-19.29%)
Paul Tudor Jones 11,791 sh (-72.45%)
Eaton Vance Worldwide Health Sciences Fund 546,329 sh (-17.92%)
» More
Q2 2017

MDT Guru Trades in Q2 2017

Jim Simons 434,000 sh (New)
Ken Fisher 183,765 sh (+2484.96%)
Joel Greenblatt 441,394 sh (+96.26%)
HOTCHKIS & WILEY 2,227,597 sh (+80.26%)
Paul Tudor Jones 19,585 sh (+66.10%)
John Buckingham 19,727 sh (+8.54%)
Jeremy Grantham 4,372,844 sh (+3.97%)
Diamond Hill Capital 2,679,692 sh (+3.15%)
Mairs and Power 3,485,426 sh (+0.33%)
David Carlson 970,000 sh (unchged)
First Eagle Investment 1,434 sh (unchged)
NWQ Managers 3,432 sh (unchged)
Caxton Associates 6,900 sh (unchged)
Bill Nygren 2,440,000 sh (unchged)
Richard Pzena Sold Out
Ruane Cunniff Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jeff Auxier 146,998 sh (-0.02%)
Mario Gabelli 25,670 sh (-0.74%)
T Rowe Price Equity Income Fund 2,706,600 sh (-1.58%)
Barrow, Hanley, Mewhinney & Strauss 19,685,524 sh (-2.58%)
Pioneer Investments 4,891,310 sh (-4.70%)
Dodge & Cox 11,583,871 sh (-5.15%)
Manning & Napier Advisors, Inc 5,198,146 sh (-8.24%)
PRIMECAP Management 9,868,910 sh (-11.04%)
Vanguard Health Care Fund 16,509,984 sh (-11.99%)
Robert Olstein 91,150 sh (-24.67%)
Eaton Vance Worldwide Health Sciences Fund 70,571 sh (-87.08%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -2.58%0.06%$80.01 - $89.3 $ 79.55-6%19,685,524
Vanguard Health Care Fund 2017-06-30 Reduce -11.99%0.41%$80.01 - $89.3 $ 79.55-6%16,509,984
Dodge & Cox 2017-06-30 Reduce -5.15%0.04%$80.01 - $89.3 $ 79.55-6%11,583,871
T Rowe Price Equity Income Fund 2017-06-30 Reduce -1.58%0.02%$80.01 - $89.3 $ 79.55-6%2,706,600
HOTCHKIS & WILEY 2017-06-30 Add 80.26%0.35%$80.01 - $89.3 $ 79.55-6%2,227,597
Joel Greenblatt 2017-06-30 Add 96.26%0.27%$80.01 - $89.3 $ 79.55-6%441,394
Ken Fisher 2017-06-30 Add 2484.96%0.03%$80.01 - $89.3 $ 79.55-6%183,765
Robert Olstein 2017-06-30 Reduce -24.67%0.31%$80.01 - $89.3 $ 79.55-6%91,150
Mario Gabelli 2017-06-30 Reduce -0.74%$80.01 - $89.3 $ 79.55-6%25,670
Richard Pzena 2017-06-30 Sold Out $80.01 - $89.3 $ 79.55-6%0
Ruane Cunniff 2017-06-30 Sold Out $80.01 - $89.3 $ 79.55-6%0
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -1.57%0.03%$70.61 - $83.3 $ 79.552%20,205,859
Vanguard Health Care Fund 2017-03-31 Reduce -2.58%0.08%$70.61 - $83.3 $ 79.552%18,760,219
Dodge & Cox 2017-03-31 Add 14.25%0.1%$70.61 - $83.3 $ 79.552%12,212,276
T Rowe Price Equity Income Fund 2017-03-31 Add 51.93%0.35%$70.61 - $83.3 $ 79.552%2,750,000
Bill Nygren 2017-03-31 Add 48.78%0.4%$70.61 - $83.3 $ 79.552%2,440,000
HOTCHKIS & WILEY 2017-03-31 Reduce -1.24%$70.61 - $83.3 $ 79.552%1,235,797
Joel Greenblatt 2017-03-31 New Buy0.23%$70.61 - $83.3 $ 79.552%224,898
Robert Olstein 2017-03-31 Add 10.00%0.11%$70.61 - $83.3 $ 79.552%121,000
Mario Gabelli 2017-03-31 Reduce -3.41%$70.61 - $83.3 $ 79.552%25,861
Ken Fisher 2017-03-31 Add 16.62%$70.61 - $83.3 $ 79.552%7,109
Richard Pzena 2017-03-31 Add 6.37%$70.61 - $83.3 $ 79.552%4,560
NWQ Managers 2017-03-31 New Buy$70.61 - $83.3 $ 79.552%3,432
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Add 7.86%0.16%$71.23 - $86.39 $ 79.551%20,528,595
Vanguard Health Care Fund 2016-12-31 Add 2.71%0.09%$71.23 - $86.39 $ 79.551%19,256,523
Dodge & Cox 2016-12-31 Add 91.39%0.32%$71.23 - $86.39 $ 79.551%10,688,625
T Rowe Price Equity Income Fund 2016-12-31 Add 141.33%0.35%$71.23 - $86.39 $ 79.551%1,810,000
Bill Nygren 2016-12-31 Add 43.86%0.23%$71.23 - $86.39 $ 79.551%1,640,000
HOTCHKIS & WILEY 2016-12-31 Add 23.54%0.07%$71.23 - $86.39 $ 79.551%1,251,351
Robert Olstein 2016-12-31 Add 127.12%0.57%$71.23 - $86.39 $ 79.551%110,000
Mario Gabelli 2016-12-31 Add 1.91%$71.23 - $86.39 $ 79.551%26,774
Ken Fisher 2016-12-31 Add 23.18%$71.23 - $86.39 $ 79.551%6,096
Richard Pzena 2016-12-31 New Buy$71.23 - $86.39 $ 79.551%4,287
First Eagle Investment 2016-12-31 Reduce -99.64%0.09%$71.23 - $86.39 $ 79.551%1,434
Keeley Asset Management Corp 2016-12-31 Sold Out 0.04%$71.23 - $86.39 $ 79.551%0
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce -9.75%0.27%$84.68 - $88.92 $ 79.55-9%19,033,448
Vanguard Health Care Fund 2016-09-30 Reduce -2.15%0.08%$84.68 - $88.92 $ 79.55-9%18,747,933
Dodge & Cox 2016-09-30 Reduce -13.44%0.07%$84.68 - $88.92 $ 79.55-9%5,584,858
Bill Nygren 2016-09-30 Reduce -54.22%0.81%$84.68 - $88.92 $ 79.55-9%1,140,000
HOTCHKIS & WILEY 2016-09-30 Reduce -38.75%0.24%$84.68 - $88.92 $ 79.55-9%1,012,932
First Eagle Investment 2016-09-30 Reduce -64.10%0.15%$84.68 - $88.92 $ 79.55-9%397,038
Robert Olstein 2016-09-30 Reduce -26.62%0.2%$84.68 - $88.92 $ 79.55-9%48,432
Mario Gabelli 2016-09-30 Reduce -23.37%$84.68 - $88.92 $ 79.55-9%26,273
Ken Fisher 2016-09-30 Add 4.94%$84.68 - $88.92 $ 79.55-9%4,949
Ruane Cunniff 2016-09-30 Reduce -11.63%$84.68 - $88.92 $ 79.55-9%3,000
Joel Greenblatt 2016-09-30 Sold Out 0.17%$84.68 - $88.92 $ 79.55-9%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare: » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDTN.Mexico, MDT.Switzerland, 0QYG.UK,
Headquarter Location:Ireland
Medtronic PLC is a medical technology company. It primarily manufacture and sell device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments.

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for about 45% of the company's total sales.

Guru Investment Theses on Medtronic PLC

Jeff Auxier Comments on Medtronic - Aug 03, 2017

Deeply oversold in 2016 political uncertainties, the world's largest standalone medical technology company rebounded sharply for the quarter. A leader in biomedical devices, they sold their medical supplies business for $6.1 billion and will pay down debt and repurchase shares.


From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Medtronic plc - May 09, 2017

Medtronic is a leader in implantable biomedical devices. Back in 2001 the stock traded at 37.5 times earnings and this past quarter traded down to 13 times earnings with a fortress balance sheet and a 7% free cash flow yield. They continue to be a leader in medical technology as their world’s smallest pacemaker, Micra, accelerates US sales driving pacemaker market growth. They generate over $5 billion in free cash flow annually.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Gabelli Funds Comments on Medtronic Plc - Aug 04, 2016

Medtronic plc (NYSE:MDT) (1.7%) (MDT – $75.00 – NYSE) cemented its position as the largest manufacturer of medical devices in the world with last year’s $50 billion acquisition of Covidien. This deal, structured as a tax inversion, should both improve the company’s growth rate and give it better access to its global cash flow. Meanwhile, Medtronic is accelerating its own growth rate through improved management execution and a full pipeline of new heart valves, drug coated balloons, and defibrillators. Medtronic will be the partner of choice for hospitals going forward, and the Covidien deal will allow the company to continue to return at least 50% of its cash flow to shareholders via share buybacks and dividends.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Medtronic PLC

Medtronic Named Best Company to Work For in New Hampshire Fourth Year in a Row
3 Bear Stocks for Today Coty, Redfin and Medtronic are trading lower despite optimism in US markets
Coty Inc. (NYSE:COTY) fell more than 12% as the company posted adjusted fourth-quarter EPS of zero cents on revenue of $2.24 billion, coming short of profit estimates by nine cents per share but beating revenue expectations by $80 million. Revenue increased 5% for the combined company (revenues of Coty and the P&G Beauty Business) at constant currency compared to the previous year. Excluding the effect of the acquisitions of ghd and Younique, combined organic net revenues declined 3% on a constant currency basis. Moreover; adjusted operating income reached $90.1 million and decreased from $94.2 million in the previous period. The bottom line was also affected, with reported EPS of -41 cents declining from negative nine cents a year ago. Further, adjusted EPS of zero cents decreased from 13 cents. Read more...
Vanguard Sells Medtronic, Cigna in 2nd Quarter Largest sales of the most recent quarter
Vanguard Health Care Fund (Trades, Portfolio) owns a portfolio composed of 74 stocks with a total value of $46.532 billion. During the second quarter the guru sold shares in the following stocks: Read more...
Jeff Auxier Comments on Medtronic Guru stock highlight
Deeply oversold in 2016 political uncertainties, the world's largest standalone medical technology company rebounded sharply for the quarter. A leader in biomedical devices, they sold their medical supplies business for $6.1 billion and will pay down debt and repurchase shares.
Read more...
High-Quality Stocks Gurus Are Buying Stocks with high business predictability ratings
According to GuruFocus’ All-in-One Screener, the following stocks have high business predictability ratings, and total returns since the beginning of the year are positive. At least five gurus are shareholders in the companies. Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medtronic plc - MDT
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Medtronic plc (MDT)
The Compounding and Value Connection Jeff Auxier likes to let compounding grow his assets, but compounding doesn’t work well without minimizing losses
Weekly Top Insider Buys Highlight for the Week of June 23 The largest Insider Buys were for Medtronic PLC, Energy Transfer Partners LP, Williams Companies and Coty
The largest Insider Buys this week were for Medtronic PLC (NYSE:MDT), Energy Transfer Partners LP (NYSE:ETP), Williams Companies Inc. (NYSE:WMB) and Coty Inc. (NYSE:COTY). Read more...
InvestorsObserver releases covered-call options reports for Delek US Holdings, Devon Energy, Medtronic, Tiffany & Company and Ulta Salon Cosmetics & Fragrance Inc.

Ratios

vs
industry
vs
history
PE Ratio 26.99
MDT's PE Ratio is ranked higher than
50% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. MDT: 26.99 )
Ranked among companies with meaningful PE Ratio only.
MDT' s PE Ratio Range Over the Past 10 Years
Min: 10.17  Med: 21.07 Max: 54.09
Current: 26.99
10.17
54.09
Forward PE Ratio 16.92
MDT's Forward PE Ratio is ranked higher than
88% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. MDT: 16.92 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.99
MDT's PE Ratio without NRI is ranked higher than
51% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. MDT: 26.99 )
Ranked among companies with meaningful PE Ratio without NRI only.
MDT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.17  Med: 21.07 Max: 54.09
Current: 26.99
10.17
54.09
Price-to-Owner-Earnings 21.94
MDT's Price-to-Owner-Earnings is ranked higher than
69% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 36.31 vs. MDT: 21.94 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MDT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.24  Med: 18.96 Max: 37.87
Current: 21.94
9.24
37.87
PB Ratio 2.15
MDT's PB Ratio is ranked higher than
59% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. MDT: 2.15 )
Ranked among companies with meaningful PB Ratio only.
MDT' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 2.76 Max: 6.08
Current: 2.15
1.78
6.08
PS Ratio 3.70
MDT's PS Ratio is ranked lower than
60% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. MDT: 3.70 )
Ranked among companies with meaningful PS Ratio only.
MDT' s PS Ratio Range Over the Past 10 Years
Min: 1.92  Med: 3.53 Max: 5.45
Current: 3.7
1.92
5.45
Price-to-Free-Cash-Flow 22.79
MDT's Price-to-Free-Cash-Flow is ranked higher than
67% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. MDT: 22.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MDT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.18  Med: 14.77 Max: 55.92
Current: 22.79
9.18
55.92
Price-to-Operating-Cash-Flow 18.28
MDT's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. MDT: 18.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MDT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.13  Med: 12.84 Max: 25.78
Current: 18.28
8.13
25.78
EV-to-EBIT 21.90
MDT's EV-to-EBIT is ranked higher than
51% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. MDT: 21.90 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 15.9 Max: 31.1
Current: 21.9
8.7
31.1
EV-to-EBITDA 14.83
MDT's EV-to-EBITDA is ranked higher than
55% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. MDT: 14.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 13.3 Max: 23.6
Current: 14.83
7.3
23.6
EV-to-Revenue 4.34
MDT's EV-to-Revenue is ranked lower than
59% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. MDT: 4.34 )
Ranked among companies with meaningful EV-to-Revenue only.
MDT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 3.5 Max: 6.4
Current: 4.34
2.3
6.4
PEG Ratio 6.66
MDT's PEG Ratio is ranked lower than
81% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. MDT: 6.66 )
Ranked among companies with meaningful PEG Ratio only.
MDT' s PEG Ratio Range Over the Past 10 Years
Min: 1.1  Med: 2.19 Max: 25.64
Current: 6.66
1.1
25.64
Shiller PE Ratio 27.45
MDT's Shiller PE Ratio is ranked higher than
75% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 49.44 vs. MDT: 27.45 )
Ranked among companies with meaningful Shiller PE Ratio only.
MDT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.42  Med: 23.26 Max: 44.15
Current: 27.45
14.42
44.15
Current Ratio 1.64
MDT's Current Ratio is ranked lower than
70% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. MDT: 1.64 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.37 Max: 6.8
Current: 1.64
0.88
6.8
Quick Ratio 1.40
MDT's Quick Ratio is ranked lower than
61% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. MDT: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.86 Max: 6.46
Current: 1.4
0.66
6.46
Days Inventory 139.27
MDT's Days Inventory is ranked lower than
54% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. MDT: 139.27 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 132.14  Med: 142.57 Max: 164.01
Current: 139.27
132.14
164.01
Days Sales Outstanding 70.53
MDT's Days Sales Outstanding is ranked higher than
50% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. MDT: 70.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.69  Med: 81.9 Max: 92.09
Current: 70.53
68.69
92.09
Days Payable 68.45
MDT's Days Payable is ranked higher than
57% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. MDT: 68.45 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 39.63  Med: 54.03 Max: 93.14
Current: 68.45
39.63
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.19
MDT's Dividend Yield % is ranked higher than
74% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 1.14 vs. MDT: 2.19 )
Ranked among companies with meaningful Dividend Yield % only.
MDT' s Dividend Yield % Range Over the Past 10 Years
Min: 0.76  Med: 1.94 Max: 2.93
Current: 2.19
0.76
2.93
Dividend Payout Ratio 0.59
MDT's Dividend Payout Ratio is ranked lower than
59% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 0.37 vs. MDT: 0.59 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MDT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.61
Current: 0.59
0.26
0.61
3-Year Dividend Growth Rate 15.40
MDT's 3-Year Dividend Growth Rate is ranked higher than
61% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 11.10 vs. MDT: 15.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MDT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 7.6  Med: 16.7 Max: 30.2
Current: 15.4
7.6
30.2
Forward Dividend Yield % 2.27
MDT's Forward Dividend Yield % is ranked higher than
70% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 1.51 vs. MDT: 2.27 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.86
MDT's 5-Year Yield-on-Cost % is ranked higher than
81% of the 235 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MDT: 3.86 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MDT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.36  Med: 3.48 Max: 5.26
Current: 3.86
1.36
5.26
3-Year Average Share Buyback Ratio -11.10
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. MDT: -11.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: -0.2 Max: 2.5
Current: -11.1
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.23
MDT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. MDT: 1.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.97 Max: 8.6
Current: 1.23
0.76
8.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.52
MDT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
63% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 2.12 vs. MDT: 2.52 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MDT' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 1.49 Max: 4.69
Current: 2.52
0.54
4.69
Price-to-Median-PS-Value 1.05
MDT's Price-to-Median-PS-Value is ranked lower than
61% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. MDT: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.16 Max: 3.58
Current: 1.05
0.42
3.58
Earnings Yield (Greenblatt) % 4.57
MDT's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. MDT: 4.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 11.5
Current: 4.57
3.2
11.5
Forward Rate of Return (Yacktman) % 8.63
MDT's Forward Rate of Return (Yacktman) % is ranked lower than
52% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.78 vs. MDT: 8.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 6.6  Med: 13.7 Max: 19.5
Current: 8.63
6.6
19.5

More Statistics

Revenue (TTM) (Mil) $29,934.00
EPS (TTM) $ 2.97
Beta0.82
Short Percentage of Float0.57%
52-Week Range $69.35 - 89.72
Shares Outstanding (Mil)1,358.58

Analyst Estimate

Apr18 Apr19 Apr20
Revenue (Mil $) 29,872 31,266 32,805
EPS ($) 4.90 5.32 5.73
EPS without NRI ($) 4.90 5.32 5.73
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.80%
Dividends per Share ($) 1.89 2.09 2.47
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Medtronic Named Best Company to Work For in New Hampshire Fourth Year in a Row Sep 07 2017 
3 Bear Stocks for Today Aug 22 2017 
Vanguard Sells Medtronic, Cigna in 2nd Quarter Aug 17 2017 
Jeff Auxier Comments on Medtronic Aug 03 2017 
United Therapeutics Exhibits Some Value Jul 20 2017 
High-Quality Stocks Gurus Are Buying Jul 19 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medtronic plc - Jul 18 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Medtronic plc (MDT) Jul 18 2017 
The Compounding and Value Connection Jul 13 2017 
Better Dividend Aristocrat: Johnson & Johnson or Medtronic? Jul 13 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Medtronic PLC. Sep 19 2017
3 Innovation-Forward Healthcare Stocks to Buy Now Sep 19 2017
5 Ways To Play 2017’s Biotech Boom Sep 13 2017
New Five-Year Gender Subset Data from the Medtronic Engage Registry Presented in VIVA Late... Sep 13 2017
Medtronic Looks Vulnerable to a Bigger Decline Sep 13 2017
Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm Sep 13 2017
Medtronic Launches StealthStation Technology, Expands in ENT Sep 13 2017
Corporate News Blog - Medtronic Voluntarily Recalls Diabetes Infusion Sets Worldwide Sep 13 2017
Medtronic (MDT) Begins Product Recall, Diabetes Group a Drag Sep 12 2017
Medtronic Announces New StealthStation(TM) Technology for Ear, Nose, and Throat Procedures Sep 12 2017
Medtronic to recall some diabetes infusion sets Sep 11 2017
Earnings Review and Free Research Report: Medtronic's Q1 Non-GAAP EPS Grew 9% Y-o-Y; Topped... Sep 11 2017
Medtronic recalls diabetes infusion sets given risk of over-delivery of insulin Sep 11 2017
Medtronic Announces Voluntary Recall of Diabetes Infusion Sets Sep 11 2017
Is a Med-Tech Marriage in Mazor Robotics' Future? Sep 10 2017
3 Stocks at 52-Week Highs Still Worth Buying Sep 09 2017
Medtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon Sep 08 2017
Are These Healthcare Stocks Top Takeover Targets? Sep 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}